JP2025502147A5 - - Google Patents

Info

Publication number
JP2025502147A5
JP2025502147A5 JP2024541604A JP2024541604A JP2025502147A5 JP 2025502147 A5 JP2025502147 A5 JP 2025502147A5 JP 2024541604 A JP2024541604 A JP 2024541604A JP 2024541604 A JP2024541604 A JP 2024541604A JP 2025502147 A5 JP2025502147 A5 JP 2025502147A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
compound according
group
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024541604A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502147A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/010514 external-priority patent/WO2023137026A1/en
Publication of JP2025502147A publication Critical patent/JP2025502147A/ja
Publication of JP2025502147A5 publication Critical patent/JP2025502147A5/ja
Pending legal-status Critical Current

Links

JP2024541604A 2022-01-12 2023-01-10 タンパク質中のグルタミン残基にコンジュゲートしたカンプトテシンアナログおよびその使用 Pending JP2025502147A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263298786P 2022-01-12 2022-01-12
US63/298,786 2022-01-12
PCT/US2023/010514 WO2023137026A1 (en) 2022-01-12 2023-01-10 Camptothecin analogs conjugated to a glutamine residue in a protein, and their use

Publications (2)

Publication Number Publication Date
JP2025502147A JP2025502147A (ja) 2025-01-24
JP2025502147A5 true JP2025502147A5 (enExample) 2026-01-08

Family

ID=85222406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024541604A Pending JP2025502147A (ja) 2022-01-12 2023-01-10 タンパク質中のグルタミン残基にコンジュゲートしたカンプトテシンアナログおよびその使用

Country Status (9)

Country Link
US (1) US20230287138A1 (enExample)
EP (1) EP4463187A1 (enExample)
JP (1) JP2025502147A (enExample)
KR (1) KR20240134010A (enExample)
CN (1) CN118829449A (enExample)
AU (1) AU2023207960A1 (enExample)
CA (1) CA3241734A1 (enExample)
MX (1) MX2024008640A (enExample)
WO (1) WO2023137026A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116390771A (zh) 2020-07-13 2023-07-04 瑞泽恩制药公司 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
WO2023178289A2 (en) * 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
WO2024138000A1 (en) * 2022-12-21 2024-06-27 Regeneron Pharmaceuticals, Inc. Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
WO2024168199A1 (en) * 2023-02-09 2024-08-15 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates via inverse electron demand diels-alder reactions
EP4720075A1 (en) * 2023-05-26 2026-04-08 NJ Bio, Inc. Topoisomerase inhibitors, methods of making, and methods of use thereof
WO2025042953A1 (en) * 2023-08-22 2025-02-27 The Research Foundation For The State University Of New York Antibody-drug complexes with topoisomerase inhibitors
WO2025082990A1 (en) * 2023-10-15 2025-04-24 Araris Biotech Ag Antibody-drug conjugates using two different types of topoisomerase i inhibitors
CN120053678A (zh) * 2023-11-30 2025-05-30 上海医药集团股份有限公司 一种高喜树碱类抗体偶联药物、其制备方法及应用
WO2025199666A1 (en) * 2024-03-25 2025-10-02 Canwell Biotech Limited Multivalent linkers for high loading antibody-drug conjugates, and compositions and methods thereof
WO2026013234A1 (en) * 2024-07-10 2026-01-15 Araris Biotech Ag Triple-payload antibody-drug conjugates (adcs)
WO2026046398A1 (en) * 2024-08-30 2026-03-05 Hansoh Bio Llc Novel camptothecin derivative and conjugate thereof, preparation method therefor and application thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9510716D0 (en) * 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
CN100406460C (zh) 2003-11-10 2008-07-30 中国科学院上海药物研究所 喜树碱的新衍生物、制备方法和用途
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
CN1587265A (zh) 2004-07-08 2005-03-02 浙江大学 10-烷氧基喜树碱衍生物及其制备方法与应用
JP2008521828A (ja) 2004-11-29 2008-06-26 シアトル ジェネティックス, インコーポレイテッド 操作された抗体およびイムノコンジュゲート
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
EP2167963B1 (en) 2007-05-23 2019-04-17 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
AU2009275358C1 (en) 2008-07-21 2015-09-24 Polytherics Limited Novel reagents and method for conjugating biological molecules
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
AU2010283632B2 (en) 2009-08-10 2016-08-25 Ucl Business Plc Reversible covalent linkage of functional molecules
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
SMT201700023T1 (it) 2010-08-02 2017-03-08 Regeneron Pharma Topi che producono proteine leganti vl
CN110078789A (zh) 2011-05-27 2019-08-02 Ambrx 公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
BR112014009070B1 (pt) 2011-10-14 2021-11-23 Medimmune Limited Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas
EP2751111B1 (en) 2011-10-14 2017-04-26 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases
CN103997893B (zh) 2011-10-14 2019-04-12 西雅图基因公司 吡咯并苯并二氮杂卓和靶向结合物
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
RU2014124984A (ru) 2011-12-05 2016-01-27 Идженика Биотерапьютикс, Инк. Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы
CN105142672B (zh) 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
KR102445502B1 (ko) * 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
US9951141B2 (en) 2014-06-02 2018-04-24 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates, their preparation and their therapeutic use
BR112018014759B1 (pt) 2016-01-25 2024-02-27 Regeneron Pharmaceuticals, Inc Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso
EP3419670A2 (en) 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
WO2018026742A1 (en) * 2016-08-01 2018-02-08 Askgene Pharma Inc. Novel antibody-albumin-drug conjugates (aadc) and methods for using them
ES3046537T3 (en) 2016-11-08 2025-12-02 Regeneron Pharma Steroids and protein-conjugates thereof
JP7381478B2 (ja) * 2017-10-23 2023-11-15 マブリンク ビオシオンス 単一分子量ポリサルコシンを含むリガンド-薬物-複合体
KR102871690B1 (ko) 2018-04-30 2025-10-16 리제너론 파마슈티칼스 인코포레이티드 Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도
CN118955710A (zh) * 2018-05-09 2024-11-15 里珍纳龙药品有限公司 抗msr1抗体及其使用方法
SG11202010496WA (en) * 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
BR112021013464A2 (pt) 2019-01-08 2021-09-21 Regeneron Pharmaceuticals, Inc. Ligantes sem traço e conjugados de proteína dos mesmos
EP3976112A1 (en) * 2019-06-03 2022-04-06 Synaffix B.V. Acetal-based cleavable linkers
KR20220148200A (ko) * 2020-02-28 2022-11-04 리제너론 파마슈티칼스 인코포레이티드 Her2에 결합하는 이중특이적 항원 결합 분자 및 이의 사용 방법
CN116390771A (zh) * 2020-07-13 2023-07-04 瑞泽恩制药公司 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途
AU2021335257A1 (en) * 2020-09-04 2023-03-09 Merck Patent Gmbh Anti-CEACAM5 antibodies and conjugates and uses thereof
BR112023019495A2 (pt) * 2021-03-30 2023-11-07 Centre Nat Rech Scient Ligante de autorreação induzida por enzima tendo propriedades fisicoquímicas e farmacológicas melhoradas
GEAP202416409A (en) * 2021-05-07 2024-02-26 Alx Oncology Inc Exatecan derivatives and antibody-drug conjugates thereof
JP2024521629A (ja) * 2021-06-02 2024-06-04 シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド 抗体薬物コンジュゲート、及びその調製方法及びその使用
JP2025525296A (ja) * 2022-06-27 2025-08-05 トライオール インコーポレイテッド 自壊性基を含む化合物及びそれを含むリガンド-薬物コンジュゲート

Similar Documents

Publication Publication Date Title
JP2025502147A5 (enExample)
JP2023534437A5 (enExample)
JP7854492B2 (ja) 抗体-ピロロベンゾジアゼピン誘導体コンジュゲート
JP6908656B2 (ja) 薬物結合体のためのスルホンアミド含有連結系
JP2023106627A (ja) Peg化薬物リンカー及びその中間体を調製するためのプロセス
CN115315263A (zh) 细胞表面受体结合化合物和缀合物
JP7605290B2 (ja) 化合物またはその塩、およびそれらにより得られる抗体
TW200302227A (en) Geranyl group-containing compounds
JP2022540395A (ja) 細胞結合性分子-チューブリシン誘導体共役体及びその調製方法
JP7658450B2 (ja) 抗体および機能性物質の位置選択的なコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩
JP2025512735A5 (enExample)
JP2025111561A (ja) 化合物またはその塩、およびそれらにより得られる抗体
JP2025124732A (ja) 化合物またはその塩、およびそれらにより得られる抗体
WO2024210154A1 (ja) 抗体および機能性物質のコンジュゲート、抗体誘導体ならびに化合物、またはそれらの塩
WO2010010912A1 (ja) BSHを導入した光学活性なα-アミノ酸類およびその合成方法
CN112996778A (zh) 制备微管溶素及其中间体的替代方法
WO2023054706A1 (ja) 抗体および機能性物質のコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩
CN120344544A (zh) 糖皮质激素受体激动剂及其偶联物
JP2024512046A5 (enExample)
WO2024235071A1 (en) Conjugate and the preparation thereof
JP2026048648A (ja) 癌を治療するための組み合わせ療法
KR101597105B1 (ko) 항체-링커-약물 결합체, 그의 제조방법 및 그를 포함하는 항암제 조성물
CN118119639A (zh) 抗体和功能性物质的缀合物或其盐、以及其制造中使用的抗体衍生物和化合物或它们的盐
KR101597110B1 (ko) 항체-링커-약물 결합체, 그의 제조방법 및 그를 포함하는 항암제 조성물
TW202535884A (zh) 從生物活性化合物的偶聯物的選擇性藥物釋放